News

ivWatch Announces Federal Distribution Agreement with Marathon Medical Corp.

ivWatch, LLC, the IV safety company, today announced it has entered into a distribution agreement with Marathon Medical Corp., a medical supply distribution company and service-disabled veteran-owned small business (SDVOSB) focused on providing a range of medical products to Federal healthcare agencies. ivWatch’s patient monitoring technology helps protect patients from unpredictable IV complications with early IV infiltration and extravasation detection.

Under the terms of the multi-year agreement, Marathon Medical will distribute the ivWatch patient monitoring system in the United States to VA hospitals and clinics, Indian Health Service hospitals and clinics, and other Federal agencies. In conjunction with the partnership, ivWatch products will be added to Marathon’s FSS/GSA contracts, significantly increasing visibility, and providing direct access to ivWatch technology for advancing IV therapy.

With over 30 clinical studies and more than 20 years of research and development completed, ivWatch products use a predictive algorithm combined with multi-spectral light to identify extravasations at the earliest onset of fluid leaking outside of the vein. Every extravasation is a medication dosing error and can lead to severe outcomes such as nerve damage, scarring, skin necrosis, and even amputation, in the most serious instances. ivWatch and Marathon Medical will work in partnership to provide clinical vascular access education services, product evaluations for facilities to understand how the technology seamlessly integrates into their workflow, and product implementation support.

ivWatch’s president and CEO Gary Warren was particularly passionate about securing this partnership as a former 14-year federal employee of NASA and someone whose family history is deeply rooted in the military, with multiple generations having served – including three of his sons who served or are currently serving in the Navy.

“ivWatch and Marathon Medical share the same belief in the importance of standing up, speaking up and fighting for better patient safety – and that determination combined with our shared employee cultures of empathy and selflessness define our partnership,” said Warren. “I knew from the moment I walked into their headquarters and met John and his team that our collective future would involve taking immediate action in our communities – mobilizing our veterans and frontline workers and making a positive difference in IV therapy outcomes. Every day we are on a mission to end this silent extravasation epidemic and empower patients, many of whom have already endured extensive pain and hardship.”

Marathon Medical was founded in 2002 by Vietnam-era veteran John St. Leger and is committed to the patient first and foremost. The company, whose manufacturing partners include Abbott, Braun Medical, Medtronic, PDI and others, remembers, honors, and gives back to the community it serves by donating to the Navy SEAL Foundation, American Military Family, and Tails of Valor. 

Noted St. Leger, “We’re passionate about helping keep our US military, Federal employee, and Native American communities healthy and safe, and ivWatch aligns perfectly with that mission. We’re thrilled to partner with and support a fellow small business to improve IV safety through advanced technology. Together, we look forward to drastically changing the experience and outcomes of patients and improving clinical practices for frontline workers.”

To learn more about the ivWatch patient monitoring system, visit https://www.ivwatch.com/tech-overview/.

Recent News

09/30/2026

Activation Capital Recognizes President Michael Rao’s 17 Years of Leadership as Authority Board Chair, Names Paul Nolde as New Chair

Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, today announced the election of Paul Nolde as chair of the Authority Board, succeeding Virginia Commonwealth University President Michael Rao, Ph.D., who has served as chair since 2009. Rao will remain an active member of the board, continuing his longstanding support of Activation …

09/22/2026

ATCC to Lead Lifecycle Management of Military Medical Countermeasures Under 10-Year Department of War Contract

ATCC has been awarded a 10-year Department of War (DOW) contract to coordinate lifecycle management of medical countermeasures (MCMs) developed to protect U.S. military personnel from chemical and biological threats. Under this contract, ATCC supports the mission of the Rapid Access to Products in Development (RAPID) program to enable MCM preparedness against chemical and biological …

09/22/2026

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 for the treatment of Peeling Skin Syndrome (PSS). QRX003 is an investigational topical serine protease inhibitor lotion. …